Oncotelic Therapeutics, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Oncotelic Therapeutics, Inc. (OTLC) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $500.00 thousand as of 2023-06-30, per its 10-Q filed 2023-08-18.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2023-11-14
- 2023-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $500.00K.
- 2023-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$500.00K.
- 2022-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $500.00K; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net as first filed -$500.00K.
- 2022-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net -$500.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net as first filed |
|---|---|---|
| 2023-06-30 | $500.00K 10-Q · filed 2023-08-18 | |
| 2023-03-31 | -$500.00K 10-Q · filed 2023-05-22 | |
| 2022-12-31 | $500.00K 10-Q · filed 2023-11-14 | -$500.00K 10-K · filed 2023-04-14 |
| 2022-09-30 | -$500.00K 10-Q · filed 2022-11-18 | |
| 2022-03-31 | -$1.25M 10-Q · filed 2022-05-23 | |
| 2021-12-31 | -$1.25M 10-K/A · filed 2023-04-20 |